- Home
- OXLCO vs SLRX Comparison
OXLCO vs SLRX Comparison
Compare OXLCO & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXLCO
- SLRX
- Stock Information
- Founded
- OXLCO N/A
- SLRX N/A
- Country
- OXLCO United States
- SLRX United States
- Employees
- OXLCO N/A
- SLRX N/A
- Industry
- OXLCO Investment Managers
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- OXLCO Finance
- SLRX Health Care
- Exchange
- OXLCO Nasdaq
- SLRX Nasdaq
- Market Cap
- OXLCO N/A
- SLRX 1.8M
- IPO Year
- OXLCO N/A
- SLRX N/A
- Fundamental
- Price
- OXLCO $23.34
- SLRX $0.89
- Analyst Decision
- OXLCO
- SLRX
- Analyst Count
- OXLCO 0
- SLRX 0
- Target Price
- OXLCO N/A
- SLRX N/A
- AVG Volume (30 Days)
- OXLCO N/A
- SLRX 3.5M
- Earning Date
- OXLCO N/A
- SLRX 08-08-2025
- Dividend Yield
- OXLCO N/A
- SLRX N/A
- EPS Growth
- OXLCO N/A
- SLRX N/A
- EPS
- OXLCO N/A
- SLRX N/A
- Revenue
- OXLCO N/A
- SLRX N/A
- Revenue This Year
- OXLCO N/A
- SLRX N/A
- Revenue Next Year
- OXLCO N/A
- SLRX N/A
- P/E Ratio
- OXLCO N/A
- SLRX N/A
- Revenue Growth
- OXLCO N/A
- SLRX N/A
- 52 Week Low
- OXLCO N/A
- SLRX $0.45
- 52 Week High
- OXLCO N/A
- SLRX $7.20
- Technical
- Relative Strength Index (RSI)
- OXLCO 62.56
- SLRX 49.85
- Support Level
- OXLCO $23.00
- SLRX $0.86
- Resistance Level
- OXLCO $23.29
- SLRX $1.33
- Average True Range (ATR)
- OXLCO 0.09
- SLRX 0.14
- MACD
- OXLCO 0.01
- SLRX -0.01
- Stochastic Oscillator
- OXLCO 95.83
- SLRX 38.70
About OXLCO Oxford Lane Capital Corp. Preferred Stock Shares 6.00% Series 2029
Oxford Lane Capital Corp is a non-diversified closed-end management investment company. The fund's investment objective is to maximize its portfolio's risk-adjusted total return over its investment horizon. Its current focus is to seek that return by investing in equity and junior tranches of CLO(collateralized loan obligation) vehicles, which are collateralized by a diverse portfolio of senior loans, and which generally have little to no exposure to real estate loans, mortgage loans or pools of consumer-based debt, such as credit card receivables or auto loans. Its investment plan also includes investing in warehouse facilities, which are financing structures intended to aggregate senior loans that may be used to form the basis of a CLO vehicle.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.